Last updated on July 2019

A Global Study of the Efficacy and Safety of Midostaurin + Chemotherapy in Newly Diagnosed Patients With FLT3 Mutation Negative (FLT3-MN) Acute Myeloid Leukemia (AML)

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Acute myeloid leukemia
  • Age: Between 18 - 100 Years
  • Gender: Male or Female

Inclusion Criteria:

  1. Diagnosis of AML (20% blasts in the bone marrow based on WHO 2016 classification). Patients with APL with PML-RARA are not eligible.
  2. Suitability for intensive induction chemotherapy in the judgment of the investigator
  3. Documented absence of an ITD and TKD activating mutation at codons D835 and I836 in the FLT3 gene, as determined by analysis in a Novartis designated laboratory using a validated clinical trial assay with clinical cutoff of 0.05 mutant to wild type signal ratio
  4. Age 18 years
  5. Laboratory values that indicate adequate organ function assessed locally at the screening visit

Exclusion Criteria:

  1. Central nervous system (CNS) leukemia
  2. Therapy-related secondary AML
  3. Isolated extramedullary leukemia
  4. Prior therapy for leukemia or myelodysplasia
  5. AML after antecedent myelodysplasia (MDS) with prior cytotoxic treatment (e.g., azacytidine or decitabine)
  6. Prior treatment with a FLT3 inhibitor (e.g., midostaurin, quizartinib, sorafenib)

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.